Qing-song Liu

High Magnetic Field Laboratory
Hefei, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Journal: Leukemia

Published: May 06, 2026

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.

Journal: Nature communications

Published: January 24, 2025

Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia.

Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia.

Journal: Cell death & disease

Published: October 18, 2024

Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation.

Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation.

Journal: Acta pharmacologica Sinica

Published: July 23, 2024

Synthesis of Quercetin-Acid Esters and Its Reduction of H2 O2 -Triggered PC12 Cells Damage by Down-Regulating ROS.

Synthesis of Quercetin-Acid Esters and Its Reduction of H2 O2 -Triggered PC12 Cells Damage by Down-Regulating ROS.

Journal: Chemistry & biodiversity

Published: September 29, 2022

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1.

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1.

Journal: Acta pharmacologica Sinica

Published: May 16, 2022

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.

Journal: Signal transduction and targeted therapy

Published: May 07, 2022

Copper-mediated synthesis of fullerooxazoles from [60]fullerene and N-hydroxybenzimidoyl cyanides.

Copper-mediated synthesis of fullerooxazoles from [60]fullerene and N-hydroxybenzimidoyl cyanides.

Journal: Organic & biomolecular chemistry

Published: April 07, 2022

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.

Journal: Acta pharmacologica Sinica

Published: October 06, 2021

Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.

Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.

Journal: Analytical cellular pathology (Amsterdam)

Published: August 25, 2021

A copper-promoted synthesis of epoxy-bridged [60]fullerene-fused lactones and further derivatization.

A copper-promoted synthesis of epoxy-bridged [60]fullerene-fused lactones and further derivatization.

Journal: Chemical communications (Cambridge, England)

Published: June 25, 2021

An overview of kinase downregulators and recent advances in discovery approaches.

An overview of kinase downregulators and recent advances in discovery approaches.

Journal: Signal transduction and targeted therapy

Published: May 05, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026